FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research report report published on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

FibroGen Price Performance

Shares of FibroGen stock opened at $0.33 on Monday. The firm has a market cap of $32.76 million, a price-to-earnings ratio of -0.28 and a beta of 0.82. The stock has a 50-day simple moving average of $0.35 and a 200-day simple moving average of $0.59. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter last year, the firm earned ($0.52) earnings per share. As a group, equities research analysts predict that FibroGen will post -0.86 earnings per share for the current year.

Institutional Trading of FibroGen

A number of hedge funds have recently modified their holdings of FGEN. Point72 DIFC Ltd increased its stake in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the period. Doheny Asset Management CA bought a new stake in shares of FibroGen in the 2nd quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of FibroGen in the 2nd quarter worth approximately $130,000. Sei Investments Co. lifted its position in shares of FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in FibroGen in the 2nd quarter valued at $145,000. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.